Introduction
The International Conference on Differentiation Therapy group of clinicians and researchers has met for more than 20 years and the most recent meeting in 2005 was held in Shanghai, China (1) . This group fostered the required networks to translate these novel strategies to clinical practice, as with retinoic acid (RA) differentiation therapy in acute promyelocytic leukemia (APL). The 11th International Conference on Differentiation Therapy and Innovative Therapeutics in Oncology was held between November 4 and November 8, 2006 in Versailles, France. The theme of this meeting was '' Apoptosis, Differentiation, Signaling, Epigenetics, and Beyond. . .''. Approximately 350 scientists and clinicians from more than 30 different countries participated.
A major part of this year's program was dedicated to transcriptional silencing with emphasis on epigenetics, having an important part in the diagnosis, prognostic assessment, and treatment of cancer. Another aspect was apoptosis, which determines treatment response. Understanding the molecular events regulating apoptosis in response to anticancer chemotherapy, and how cancer cells evade apoptotic death, provides novel opportunities to develop moleculartargeted therapies. Alterations in signaling pathways are involved in leukemogenesis both at the transcriptional level and downstream of membrane receptor activation. Integration of these pathways is necessary for optimal targeted approach. Other concepts were also discussed, such as cancer prevention and immunotherapy.
Apoptosis
Apoptosis of tumor cells allowed the development of inducing agents in cancer therapeutics. Seamus Martin (The Smurfit Institute, Dublin, Ireland) presented the different apoptotic and antiapoptotic molecules, identifying several novel granzyme B substrates. Raymond Warrell, Jr. (Genta Inc., Berkeley Heights, NJ) described the direct targeting of BCL-2 via an antisense oligonucleotide (Genasense), to enhance the effectiveness of standard anticancer therapy.
Arsenic trioxide (As 2 O 3 ) induces apoptosis. In a workshop on apoptosis and signaling, Samuel Waxman (Mount Sinai School of Medicine, New York, NY) described proteins targeted by As 2 O 3 . Ruibao Ren (Mount Sinai, New York, NY) reported that As 2 O 3 induces differentiation and apoptosis in vitro and reduces tumor load in vivo in some hematologic disorders. In APL and in chronic myelogenous leukemia (CML) cell lines, treatment with MEK1 inhibitors enhances the apoptosis induced by As 2 O 3 , according to Antonio Bonati (University Hospital of Parma, Parma, EmiliaRomagna, Italy). Trolox stimulates As 2 O 3 -mediated apoptosis in APL, CML, lymphoma, myeloma, and breast cancer cells as described by Wilson Miller, Jr. (McGill University, Montreal, Quebec, Canada). In a unique model of FIP1L1-platelet-derived growth factor receptor-positive cells, Carine Robert indicated that retinoids induce apoptosis and synergize with imatinib (INSERM U718, Paris, France). Catherine Brenner Jan (Université de Versailles, Versailles, France) described the implication of the adenine nucleotide translocator in cancer. Masahiro Kizaki (Keio University School of Medicine, Tokyo, Japan) reported that reactive oxygen species are mediators of apoptosis induced by a green tea polyphenol.
Differentiation
Pierre Chambon (Institut de Génétique et Biologie Moléculaire et Cellulaire, Illkirch, France) described molecular mechanisms through which both vitamin D 3 and RA signaling pathways seem to be involved in the pathogenesis of atopic diseases. Thus, cytokine thymic stromal lymphopoietin, the expression of which is induced in mice upon keratinocyte-selective ablation of retinoid X receptors (RXRa and RXRh), has a crucial role in initiating a systemic atopic dermatitis-like phenotype. Alan Rosmarin (Brown University, Providence, RI) presented the identification of a RAdependent enhanceosome in myeloid cells. Cécile Rochette-Egly (Institut de Génétique et Biologie Moléculaire et Cellulaire) discussed the integration membrane and nuclear signaling pathways, stressing the importance of aberrant kinase activities in retinoid-based cancer therapy. Sylvie Mader (Université de Montréal, Montréal, Québec, Canada) revealed that the DR2 type of the retinoic acid response element was represented in the human genome. Séverine Cathelin (INSERM U866, Dijon, France) presented proteomic analysis identifying proteins cleaved by caspases during monopoiesis. Ruud Delwel (Erasmus University Medical Center, Rotterdam, the Netherlands) reported that EVI1 interferes with erythropoiesis and that its overexpression is involved in myelodysplastic syndrome (MDS). Issai Kitabayashi (National Cancer Center Research Institute, Tokyo, Japan) described the role of MOZ [histone acetyltransferase involved in acute myelogenous leukemia (AML)] in the maintenance of hematopoietic stem cells after the generation of Moz-null mice, which died around E15.
In a session on erythropoietin, Catherine Lacombe (Institut Cochin, Paris, France) showed that the erythropoietin receptor is ubiquitinated and degraded by the proteasome. Pierre Fenaux (Hôpital Avicenne, Bobigny, France) summarized the improvements brought by erythropoietin therapy in MDS, and Paul Fisher (Columbia University, New York, NY) the follow-up in vitro of a novel differentiation protein (da-7/IL-24) in metastatic melanoma.
In the workshop ''Update of clinical trials in APL: where are we 20 years after'', Martin Tallman (Northwestern University Feinberg School of Medicine, Chicago, IL; North American APL Intergroup protocol), discussed the benefits of all-trans retinoic acid (ATRA) in induction and maintenance. Removing 1-h-D-arabinofuranosylcytosine, according to the Spanish PETHEMA (program for the study and treatment of malignant hemopathies), proved to be deleterious for high-risk patients in the randomized ''Groupe Francophone des LAP'' (Pierre Fenaux, Bobigny, France). The work of cooperative groups (Spanish PETHEMA, Italian GIMEMA, Francesco Lo Coco, Facoltà di Medicina e Chirurgia, Università di Roma, Lazio, Italy) suggest that combination of ATRA and chemotherapy for consolidation improves therapeutic results. Norio Asou (Kumamoto University Hospital, Kumamoto, Japan) presented a randomized study in newly discovered APL patients, showing no benefit for maintenance chemotherapy in PML/RARa-negative patients after consolidation. The PANDA group (M.S. Durranga-Sutton, Chile) showed how identical results might also be achieved in South America.
Arsenic trioxide is effective at inducing high rates of complete remission and molecular remission in patients with relapsed or refractory APL. Thus far, no deaths from As 2 O 3 -induced cardiac arrhythmia have been reported in 2,900 patients treated. J. Hu reported that As 2 O 3 is effective in newly diagnosed and relapsed APL (Shanghai Institute of Hematology, Shanghai, China). Other drugs added in the APL regimens are the anti-CD33 antibody linked to a toxin [Mylotarg as an additional targeted therapy (U.K., U.S., and Italian trials), and retinoids, Am80 (an RARa agonist; Japanese trials) or AS404 (China)]. Christopher Bunce (University of Birmingham, Birmingham, England, United Kingdom) described the results in AML patients with the combination of benzafibrate and medroxyprogesterone acetate.
In half of the ''poor responders'' of APL, maximal differentiation is achieved by ATRA combined with granulocyte colony-stimulating factor (Bruno Cassinat; INSERM U718, Hôpital Saint-Louis, Paris, France). Bob Gallagher (Montefiore-Einstein Cancer Center, New York, NY) identified target genes of the PML/RARa mutant. Ronan Quéré (Université de Montpellier, Montpellier, France) determined the pharmacogenomic profiles for ATRA sensitivity by comparing gene expression in ATRA ''high'' and ''low'' sensitive APL samples, and identified CYP26 as an ATRA target gene. Jiang Zhu (Shanghai Jiao-Tong University School of Medicine, Shanghai, China) reported that Rig-I as a potent effector mediating RA-induced complete remission of APL. Hugues de Thé (Institut Universitaire d'Héma-tologie, Paris, France) described the role of cyclic AMP to reverse RA-resistance conferred by a point mutation in PML/RARa, and showed that translocation-induced dimerization transforms transcription factor into a dominant oncoprotein. Akihiro Tomita (Nagoya University, Nagoya, Japan) identified new molecular targets for differentiation therapies. Eric So (Institute of Cancer Research, London, England, United Kingdom) highlighted the pathologic significance of the RARa fusion RXRa-oligomeric complex and the potential use of the RXRa as a therapeutic target in APL.
Signaling
The combined altered pathways are of prognostic significance and provide the rationale for targeted therapies. Terry Rabbitts (MRC Laboratory of Molecular Biology, Cambridge, England, United Kingdom) developed two translocation mimics (Cre-loxP recombination) to study the effect of these translocations during mouse development. Dan Tenen (Harvard Medical School, Boston, MA) identified transcriptional changes preceding malignant transformation in Pu.1À/À mice, and suggested that protein therapies based on the transduction of constitutively active CAAT/enhancer binding protein-a could be efficient in the treatment of FLT3 mutant leukemias, resistant to the FLT3 inhibitor therapies. Tomoki Naoe (Nagoya University Graduate School of Medicine, Nagoya, Japan) presented antileukemic results in mice for FI-700 (novel kinase inhibitor). Hubert Serve (University of Münster, Münster, Nordrhein-Westphalen, Germany) showed that FLT3-ITD (FLT3 alteration)-specific signals from the endoplasmic reticulum are sufficient to activate STAT5. Sai-Juan Chen (Shanghai Institute of Hematology, Shanghai, China) showed that AML1/ETO represents the first genetic hit of the disease [AML t(8;21)] whereas activation of the C-KIT pathway is a second hit for the development of a fullblown leukemia. Eric Raymond (Hôpital Beaujon, Clichy, France) reported the role of sunitinib malate in the treatment of gastrointestinal stromal tumors and renal cell carcinoma. Philip Koeffler (UCLA School of Medicine, Los Angeles, CA) discussed the use of SNP Chips in hematologic malignancies. William Vainchenker (Institut Gustave Roussy, Villejuif, France) described the role of JAK2V617F mutation leading to constitutive kinase activity. After surveying additional myeloproliferative disorders, the same mutation was found in other atypical myeloproliferative disorders. Anthony Green (University of Cambridge, Cambridge, United Kingdom) also observed a single acquired point mutation in JAK2 in patients with polycythemia vera and in half of those with either essential thrombocythemia or idiopathic myelofibrosis, allowing a new classification of myeloproliferative disorders. Finally, Richard Van Etten reported that JAK2V617F dominantly induces erythropoietin-independent expansion of the erythroid lineage (Tufts-New England Medical Center, Boston, MA).
Epigenetics
Carlo Croce (Ohio State University, Columbus, OH) described the combination of nonrandom chromosomal abnormalities and other types of genetic alterations or epigenetic events contributing to the down-regulation or overexpression of micro-RNAs. Abnormal expression of micro-RNAs affects cell cycle, survival, and differentiation programs. Selective targeting of these noncoding transcripts could provide novel therapeutic options for killing the malignant cells.
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Conclusion
After ATRA in PML/RAR+ leukemias, the International Conference on Differentiation Therapy meetings continue to foster other targeted approaches with proof of principle data and drugs obtaining regulatory approval. Focus is also aimed at adapting combinatorial targeted therapies to multitargets or different patient subgroups. Combinations of targeted agents are being addressed to improve survival and reduce chemotherapy-related toxicity. Interactions between clinical groups such as between research laboratories and clinicians were the main feature of this meeting. The active presence of all speakers and participants made the interactions profitable for everyone, including nonactive members of the group.
